Visanne (dienogest) / Mochida, Bayer - LARVOL DELTA

Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances. (PubMed, J Clin Med) - "This systematic review (2019-2025) synthesizes research results regarding the efficacy and safety of dienogest (DNG) and GnRH antagonists, while also summarizing research on new directions in endometriosis treatment...Relugolix combination therapy appears to be a more effective and safer option than elagolix or relugolix monotherapy in reducing dysmenorrhea and pelvic pain. Research concerning immunotherapy for endometriosis (using tocilizumab, anakinra, bevacizumab, and anti-CD47 antibodies) is subject to a high risk of bias and very low GRADE certainty...Research on GnRH antagonists indicates their increasing role in the future management of endometriosis. There are new perspectives in endometriosis pharmacotherapy-including immunotherapy; however, there is a fundamental need for their further development and evaluation."

Journal • Review • Endometriosis • Gynecology • Musculoskeletal Pain • Oncology • Pain • Women's Health

Presumed Hippocampal Endometriosis Presenting as Catamenial Epilepsy: Diagnostic Challenges, MRI Follow-Up, and Comparative Review of Reported Cerebral Endometriosis Case. (PubMed, J Clin Med) - "The patient received hormonal therapy with progestins, including desogestrel and dienogest, after which antiepileptic therapy was discontinued. The favorable clinical and radiological response to progestin therapy in this case adds to the limited evidence regarding conservative management of presumed cerebral endometriosis. Cerebral endometriosis is a very rare condition, and only eight case reports were found in the literature."

Journal • CNS Disorders • Endometriosis • Epilepsy • Gynecology • Infectious Disease • Musculoskeletal Pain • Oncology • Pain • Women's Health

A novel approach to treating Endometriosis-Related Repeated IVF failures- insights from single case report. (PubMed, Reprod Biol Endocrinol) - "The patient underwent Dienogest (Visabelle®) pretreatment followed by a combination protocol of Stop GnRH-agonist/GnRH-antagonist for controlled ovarian stimulation, culminating in a natural cycle frozen-thawed embryo transfer with modified luteal phase support. This combined approach produced several high-quality embryos leading to a successful singleton pregnancy. These findings provide new insights into addressing endometriosis-associated infertility and repeated IVF failure."

Journal • Endometriosis • Gynecology • Infertility • Sexual Disorders • Women's Health

Dual Intrauterine Device Placement for Refractory Endometriosis Pain in a Bicornuate Uterus: A Case Report. (PubMed, Cureus) - "She had failed treatment with an etonogestrel implant and dienogest. Dual LNG-IUS insertion under hysteroscopic guidance represents a minimally invasive and effective strategy for managing endometriosis-related pain in patients with a bicornuate uterus when conventional therapies are inadequate. Long-term follow-up and regular monitoring are warranted to assess for potential side effects."

Journal • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Musculoskeletal Pain • Pain • Women's Health

Comparative study of quality of life between endometriosis patients receiving GnRH agonist and dienogest therapy: A cross-sectional study using Endometriosis Health Profile-30 (EHP-30). (PubMed, Narra J) - "This study highlights that dienogest therapy was associated with better quality of life than GnRH agonist therapy among patients with endometriosis. These findings support the consideration of dienogest as a patient-centered hormonal option when quality of life is a major treatment priority."

Clinical • HEOR • Journal • Observational data • Endometriosis • Gynecology • Pain • Women's Health

From size to shape: morphological ultrasound remodelling of large ovarian endometriomas under dienogest therapy. (PubMed, Reprod Biomed Online) - "Dienogest is effective in reducing the volume of large ovarian endometriomas and downstaging the #Enzian score. Recognizing therapy-related TVS changes may avoid misinterpretation as atypical lesions and guide follow-up."

Journal • Endometriosis • Gynecology • Oncology • Ovarian Cancer • Pain • Solid Tumor

Real-world effectiveness and tolerability of dienogest in patients with endometriosis: a cross-sectional patient-reported-study. (PubMed, J Gynecol Obstet Hum Reprod) - "In this real-world patient-reported study, patients reported improvement under dienogest treatment, particularly for dysmenorrhea and overall quality of life. However, frequent adverse events and treatment discontinuation suggest that tolerability may limit long-term adherence."

Journal • Real-world evidence • CNS Disorders • Endometriosis • Fatigue • Gynecology • Women's Health

The Therapeutic Role of Dienogest in Endometriosis-Associated Pain: From Basics to Clinics. (PubMed, Biomolecules) - "Dienogest, as a fourth-generation selective progesterone receptor agonist, plays a key role in the treatment of endometriosis-associated pain by reducing serum estrogen levels, alleviating inflammatory responses, regulating nerve growth factor, modulating control central nervous system allergies, and influencing the biological processes of endometriotic stromal cells. Moreover, its long-term safety and tolerability are relatively satisfactory according to clinical studies, making it an effective therapeutic agent for endometriosis."

Journal • Review • Allergy • Endometriosis • Gynecology • Immunology • Inflammation • Pain • Women's Health

Effect of Dienogest in Symptomatic Endometrioma in Comparison to Combined Oral Contraceptive Pill. (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Mst.Sumyara Khatun

New trial • Endometriosis

Exploring New Treatment Strategies for Endometriosis-Narrative Review. (PubMed, Int J Mol Sci) - "The pharmacodynamic profile of Dienogest (DNG) is compared with the experience of using the pure PR antagonist Vilaprisan and the mixed PR agonist/antagonist Asoprisnil to treat endometriosis...Additionally, another SPRM, Ulipristal acetate, has been associated with rare but serious cases of liver injury...The preclinical profile of the new mesoprogestin EC313 has been presented, showing a higher PR agonistic/antagonistic quotient than Asoprisnil, with comparatively elevated anti-endometriotic activity...Based on the preclinical data currently available, the next generation of mesoprogestins warrants further investigation for the treatment of endometriosis and related gynaecological disorders. This prompts consideration of whether there is potential to enhance the effectiveness of drug discovery strategies within this particular pharmacological class."

Journal • Review • Endometriosis • Gynecology • Hepatology • Liver Failure • Pain • Solid Tumor • Uterine Leiomyoma • Women's Health • PGR

Diffuse Adenomyosis Coexisting with rASRM Stage IV Endometriosis in a Young Woman: Diagnostic Delay and Imaging Discrepancy. (PubMed, Int J Womens Health) - "Postoperatively, the patient was commenced on dienogest while awaiting future fertility treatment...Persistent dysmenorrhea in young women should not be considered a normal menstrual symptom. Early specialist referral and comprehensive multimodal imaging assessment are essential to reduce diagnostic delay, facilitate fertility-preserving management, and improve recognition of advanced adenomyosis and endometriosis."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Recurrence after hysteroscopic myomectomy for FIGO type II submucosal myomas: a retrospective cohort study. (PubMed, J Obstet Gynaecol) - "Multivariate Cox analysis identified larger myoma diameter, multiple myomas, staged operation, and longer operation time as independent risk factors, whereas older age and postoperative gonadotropin-releasing hormone agonist (GnRHa)/dienogest therapy were protective factors (P < 0.05)...The nomogram showed favourable performance, with a bootstrap-corrected C-index of 0.811, a 3-year Brier score of 0.099, and clinical net benefit across threshold probabilities of approximately 0.05-0.45. This exploratory model may support individualised 3-year recurrence risk stratification and guide follow-up and adjuvant treatment planning."

Journal • Retrospective data • Gynecology • Obstetrics • Oncology • Uterine Leiomyoma

Unexpected coexistence of diaphragmatic and abdominal wall endometriosis in a case of bilateral ovarian endometriomas: a case report. (PubMed, Front Med (Lausanne)) - "The patient received hormone therapy for 5 months, including 2 GnRH agonist injections followed by 3 months of dienogest 2 mg. Abdominal pain resolved completely, however, right-sided shoulder pain became mild and tolerable. This case emphasizes the diagnostic and surgical challenges of extra-pelvic endometriosis and highlights the need of a multidisciplinary and individualized approach."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Comment on "Dienogest Therapy against the Combined Oral Contraceptive Pill in Deep Infiltrating Endometriosis Cases: A Systematic Review and Meta-Analysis". (PubMed, Gynecol Minim Invasive Ther) - No abstract available

Journal • Retrospective data • Endometriosis • Gynecology • Women's Health

Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI (clinicaltrials.gov) - P1 | N=189 | Not yet recruiting | Sponsor: Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)

Head-to-Head • New P1 trial • Gynecology • Infertility • Sexual Disorders

Wastewater-based assessment of episodic changes in psychoactive compounds and hormones during music festivals. (PubMed, Environ Monit Assess) - "During the multi-genre music festival, the normalized mass load of 3,4-methylenedioxymethamphetamine increased by more than 110-fold on the second festival day compared to the pre-festival average, while benzoylecgonine increased approximately 17-fold and dienogest by 1.3-fold. During the country/folk music festival, tramadol loads increased approximately twofold. Principal component analysis explained 70.75% of the total variance using the first two components and revealed a clear separation between festival and background samples. Overall, the results demonstrate that music festivals represent episodic pollution events capable of markedly altering wastewater influent composition over short time periods."

Journal

Tales from the clinic: options for perimenopausal bleeding, contraception and menopausal symptom control. (PubMed, Post Reprod Health) - "This article presents three cases of women presenting in the perimenopause where alternative medical management is offered with newer hormonal therapies: Drovelis, Dydrogesterone and Dienogest. In each case, consideration is made to the management of bleeding, perimenopausal symptom control, and provision of contraception."

Journal

Adjunctive vitamin D supplementation in women receiving dienogest therapy for endometriosis: a randomized controlled trial. (PubMed, Sci Rep) - "Date of first registration 2023-05-25. URL https//irct.behdasht.gov.ir/trial/68131."

Clinical • Journal • Endometriosis • Gynecology • Inflammation • Pain • Women's Health

Primary hyperparathyroidism unmasking after dienogest-altered estrogen dynamics: implications for calcium homeostasis. (PubMed, JCEM Case Rep) - "Manifested hypercalcemia is not readily reversible, suggesting a shift to a self-sustaining state. This case raises the possibility that altered hormonal dynamics may contribute to the manifestation of PHPT."

Journal • Endocrine Disorders • Gynecology • Hematological Disorders • Metabolic Disorders • Women's Health

IMTERO: Effect of Management of the Endometrioma on Ovarian Reserve (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: University of Valencia | N=100 ➔ 0 | Trial completion date: Nov 2024 ➔ Nov 2026 | Recruiting ➔ Withdrawn | Trial primary completion date: Nov 2024 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Endometriosis

Consensus statement of dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments. (PubMed, Eur J Contracept Reprod Health Care) - "Dienogest, a 17a-cyanomethyl-17ß-hydroxy-4,9-estradien-3-one progestin is used in different dosage regimes with different oestrogens and with different release forms in contraception and has, depending on the type of COC additional medical treatment indications. This narrative review will focus on the effects, apart from contraception, of these COCs on female target organs like the uterus and the skin and clinical entities as the polycystic ovarian syndrome (PCOS)."

Journal • Review • Acne Vulgaris • Polyendocrine Metabolic Ovarian Syndrome

Preserved large elastic arterial stiffness and impaired conduit artery endothelial function in patients with endometriosis receiving progestin therapy: A cross-sectional observational study. (PubMed, Int J Gynaecol Obstet) - "Women with ovarian endometriosis, the majority of whom were receiving Dienogest therapy, demonstrated impaired endothelial function and elevated systemic inflammation despite preserved central arterial stiffness. These findings support the concept of endometriosis as a systemic inflammatory condition associated with early functional vascular impairment."

Journal • Observational data • Endometriosis • Gynecology • Inflammation • Women's Health • CRP • EDN1

Comparative effectiveness of hormonal therapies for preventing recurrence in endometriosis: a real-world retrospective cohort study with risk factor analysis. (PubMed, BMC Womens Health) - "Among sequential GnRH-a maintenance regimens, DNG was associated with a lower recurrence rate than LNG-IUS in preventing 3‑year recurrence after laparoscopic cystectomy in this cohort. Although the recurrence rate in the DNG group was lower than that in the COC group, the difference did not reach statistical significance, indicating only a trend toward superiority. All three regimens have a favourable overall safety profile, but the LNG-IUS group has a higher incidence of spotting. Severe dysmenorrhoea, previous pelvic operation history, and r-AFS stage IV are independent risk factors for postoperative recurrence, whereas older age at surgery has a protective effect."

HEOR • Journal • Real-world evidence • Retrospective data • Endometriosis • Gynecology • Women's Health

Dienogest Therapy Against the Combined Oral Contraceptive Pill in Deep Infiltrating Endometriosis Cases: A Systematic Review and Meta-Analysis. (PubMed, Gynecol Minim Invasive Ther) - "Dienogest is an effective pain treatment and it is effective for a subgroup of patients with endometriosis and pelvic pain. It is well tolerated as a pain treatment in adenomyosis patients without complications of severe uterine enlargement or severe anemia."

Journal • Retrospective data • Endometriosis • Gynecology • Hematological Disorders • Musculoskeletal Pain • Pain • Women's Health

Epidemiology, Risk Factors, Diagnosis, and Comorbidities of Endometriosis: An Umbrella Review. (PubMed, J Clin Med) - " Endometriosis is a systemic, chronically under-diagnosed disease requiring a multidisciplinary approach. The available evidence supports dienogest as one of the preferred options for post-operative maintenance therapy, identifies multi-biomarker platforms as a promising-though not yet clinically validated-avenue for non-invasive diagnosis, and underscores the importance of incorporating psychological assessment into multidisciplinary management."

Journal • Review • CNS Disorders • Depression • Endometriosis • Gynecology • Inflammation • Mood Disorders • Psychiatry • Women's Health